|
Catalogue
Number
|
Product
|
Order number / Unit
|
|
|
1918
|
FDHT standard
|
Please inquire for customized
filling and bulk quantities.
|
|
|
Reference standard for [18F]FDHT
(16β-[18F]fluoro-5α-dihydrotestosterone)
|
|
|
|
|
|
|
|
|
Molar Mass: 308.43
|
|
|
C19H29FO2
|
|
|
[141663-88-9]
|
|
|
|
|
|
Colourless solid packaged in dark glass screw cap vials.
|
|
|
|
|
|
|
|
|
Purity: > 95 %
|
|
|
Certificates:
CoA; 1H and 19F NMR spectra
|
|
|
Chemical Name:
CA index name: Androstan-3-one, 16-fluoro-17-hydroxy-, (5α,16α,17β)-
|
|
|
Synonymes:
16β-fluoro-5α-dihydrotestosterone; 16β-Fluorodihydrotestosterone; [18F]FDHT standard
|
|
|
Literature:
Liu A. et al. Fluorine-18-Labeled Androgens: Radiochemical Synthesis and Tissue Distribution Studies on Six fluorine-Substituted Androgens, Potential Imaging Agents for Prostatic Cancer. J. Nucl. Med 1992, 33, 724-734.
|
|
|
Liu A. et al. Fluorine-18-Labeled Androgens: Radiochemical Synthesis and Tissue Distribution Studies on Six fluorine-Substituted Androgens, Potential Imaging Agents for Prostatic Cancer. J. Nucl. Med 1992, 33, 724-734.
|
|
|
Zhou D. et al. Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16α-[18F]fluoroestradiol (FES), [18F]fluoro furanylnorprogesterone (FFNP), and 16beta-[18F]fluoro-5α-dihydrotestosterone (FDHT)as radiopharmaceuticals. J. Label. Compd. Radiopharm. 2014, 5, 371-377 DOI: 10.1002/jlcr.3191
|
|
|
Dehdashti F. et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 344-350.
|
|
|
|
|
|
date of product catalogue issue:
10 May 2017
|